Article
Pediatrics
Maria Hemming-Harlo, Laura Merras-Salmio, Anne Nikkonen, Kaija-Leena Kolho
Summary: This study investigated the trough levels of vedolizumab (VDZ) in a pediatric population with inflammatory bowel disease (IBD) in a real-life setting. The results showed that trough levels of VDZ were not associated with clinical remission or continuation of treatment, while a positive response on gut inflammation after induction predicted the need for maintenance therapy.
EUROPEAN JOURNAL OF PEDIATRICS
(2023)
Review
Pharmacology & Pharmacy
Linshan Duan, Shuyu Cheng, Long Li, Yanling Liu, Dan Wang, Guoyan Liu
Summary: Inflammatory bowel disease (IBD) is a chronic intestinal inflammation caused by various factors, with Crohn's disease and ulcerative colitis being the two major types. Most commonly used drugs for IBD have adverse reactions and limited long-term efficacy, leading to challenges in treating patients. Research suggests that natural compounds with anti-inflammatory activities could offer potential therapeutic strategies for IBD.
FRONTIERS IN PHARMACOLOGY
(2021)
Article
Gastroenterology & Hepatology
Alka A. Potdar, Shishir Dube, Takeo Naito, Katherine Li, Gregory Botwin, Talin Haritunians, Dalin Li, David Casero, Shaohong Yang, Janine Bilsborough, Jacqueline G. Perrigoue, Lee A. Denson, Mark Daly, Stephan R. Targan, Phillip Fleshner, Jonathan Braun, Subra Kugathasan, Thaddeus S. Stappenbeck, Dermot P. B. McGovern
Summary: The study identified differences in intestinal ACE2 expression levels in patients with Crohn's disease and ulcerative colitis, associated with inflammation and disease severity. Treatment with anti-cytokine therapy restored ACE2 expression, potentially impacting outcomes of severe acute respiratory syndrome coronavirus 2 infection.
Review
Pharmacology & Pharmacy
Irene Marafini, Edoardo Troncone, Irene Rocchetti, Giovanni Monteleone
Summary: The study found that patients with inflammatory bowel disease treated with vedolizumab had a higher risk of respiratory infections, especially for those with ulcerative colitis.
FRONTIERS IN PHARMACOLOGY
(2021)
Review
Medicine, General & Internal
Guanglin Cui, Qingbo Fan, Zhenfeng Li, Rasmus Goll, Jon Florholmen
Summary: This review discusses the use of TNF antibodies in treating IBD and the evaluation of therapeutic efficacy using current and novel biomarkers. It emphasizes the urgent need for validation and comparison studies of promising novel biomarkers to improve their value in clinical practice.
Article
Pharmacology & Pharmacy
Sara Salvador-Martin, Bartosz Kaczmarczyk, Rebeca Alvarez, Victor Manuel Navas-Lopez, Carmen Gallego-Fernandez, Ana Moreno-Alvarez, Alfonso Solar-Boga, Cesar Sanchez, Mar Tolin, Marta Velasco, Rosana Munoz-Codoceo, Alejandro Rodriguez-Martinez, Concepcion A. Vayo, Ferran Bossacoma, Gemma Pujol-Muncunill, Maria J. Fobelo, Antonio Millan-Jimenez, Lorena Magallares, Eva Martinez-Ojinaga, Ines Loverdos, Francisco J. Eizaguirre, Jose A. Blanca-Garcia, Susana Clemente, Ruth Garcia-Romero, Vicente Merino-Bohorquez, Rafael Gonzalez de Caldas, Enrique Vazquez, Ana Dopazo, Maria Sanjurjo-Saez, Luis A. Lopez-Fernandez
Summary: This study identified overexpression of FCGR1A, FCGR1B, and GBP1 genes as potential pharmacogenomic markers of early response to anti-TNF agents in pediatric IBD patients.
Review
Biochemistry & Molecular Biology
Vishal Khatri, Ramaswamy Kalyanasundaram
Summary: This review focuses on the association between IBD and gut inflammasome, as well as recent advances in research and therapeutic strategies for IBD, discussing inflammasomes and their components, outcomes from experimental animals and human studies, inflammasome inhibitors, and developments in inflammasome-targeted therapies for IBD.
Review
Pharmacology & Pharmacy
Rocio Rivera Rodriguez, Jeremy James Johnson
Summary: Inflammatory Bowel Disease (IBD) is a chronic autoimmune disease characterized by intestinal inflammation. The incidence of IBD is rapidly increasing in newly developed countries, making it a global concern. Two major types of IBD, ulcerative colitis (UC) and Crohn's disease (CD), have different manifestations and locations of inflammation in the digestive tract. Current FDA-approved treatments for IBD are only effective for 50% of patients and come with serious side effects, highlighting the need for safer and more effective therapies. Plant-based diets, such as the Mediterranean diet rich in anti-inflammatory phytochemicals, have shown benefits in preventing and improving symptoms of IBD. Terpenes, a class of phytochemicals abundant in Mediterranean herbs and citrus fruits, have been studied for their potential to modulate inflammatory signaling in IBD. However, there is still conflicting and inconclusive evidence regarding their effectiveness. This review evaluates preclinical studies on terpenes and their impact on basic inflammatory signaling in IBD.
PHARMACOLOGY & THERAPEUTICS
(2023)
Review
Biochemistry & Molecular Biology
HyunTaek Jung, Jae Seok Kim, Keum Hwa Lee, Kalthoum Tizaoui, Salvatore Terrazzino, Sarah Cargnin, Lee Smith, Ai Koyanagi, Louis Jacob, Han Li, Sung Hwi Hong, Dong Keon Yon, Seung Won Lee, Min Seo Kim, Paul Wasuwanich, Wikrom Karnsakul, Jae Il Shin, Andreas Kronbichler
Summary: Inflammatory bowel disease (IBD) is a chronic inflammatory disease of the gastrointestinal tract that mainly affects young people. Recent studies have shown that microRNAs (miRNAs) play an important role in the pathogenesis, diagnosis, and treatment of IBD.
INTERNATIONAL JOURNAL OF BIOLOGICAL SCIENCES
(2021)
Review
Pharmacology & Pharmacy
Sara Salvador-Martin, Alejandra Melgarejo-Ortuno, Luis A. Lopez-Fernandez
Summary: The use of biological drugs in pediatric inflammatory bowel disease has shown significant improvements, and predicting response to these drugs is particularly valuable in children. Clinical, biochemical, and genetic parameters can potentially predict response to biological drugs in children with IBD.
Article
Gastroenterology & Hepatology
Uma Mahadevan, Millie D. Long, Sunanda Kane, Abhik Roy, Marla C. Dubinsky, Bruce E. Sands, Russell D. Cohen, Christina D. Chambers, William J. Sandborn
Summary: The study found that exposure to biologic, thiopurine, or combination therapy during pregnancy did not increase adverse maternal or fetal outcomes, and these treatments can be continued throughout pregnancy for women with IBD to maintain disease control.
Review
Medicine, General & Internal
Eleni Orfanoudaki, Kalliopi Foteinogiannopoulou, Eirini Theodoraki, Ioannis E. Koutroubakis
Summary: Despite advancements in inflammatory bowel disease (IBD) management, anti-TNF agents continue to be the primary treatment for Crohn's disease and ulcerative colitis. However, optimizing treatment strategies is essential due to the progressive nature of the disease and potential loss of response. This overview examines the role of therapeutic drug monitoring (TDM), combining anti-TNF with immunomodulators, and the treat-to-target approach in enhancing the efficacy and outcomes of anti-TNF treatment.
JOURNAL OF CLINICAL MEDICINE
(2023)
Article
Medicine, General & Internal
Silvia Salvatori, Francesco Baldassarre, Michelangela Mossa, Giovanni Monteleone
Summary: Long COVID is common in patients with inflammatory bowel diseases (IBD), with fatigue being the most frequent symptom. It does not influence the frequency of IBD relapses, but is more prevalent in female patients.
JOURNAL OF CLINICAL MEDICINE
(2021)
Review
Gastroenterology & Hepatology
Thomas M. Goodsall, Tran M. Nguyen, Claire E. Parker, Christopher Ma, Jane M. Andrews, Vipul Jairath, Robert Bryant
Summary: The study systematically identified ultrasound scoring indices for assessing inflammatory bowel disease activity, with common components including bowel wall thickness, colour Doppler imaging, and bowel wall stratification. The correlation between ultrasound indices and reference standards, as well as sensitivity, specificity, accuracy, and other properties, varied within certain ranges. However, reliability and responsiveness data were limited, and most studies were rated with unclear or high risk of bias.
JOURNAL OF CROHNS & COLITIS
(2021)
Review
Medicine, General & Internal
Katarzyna Akutko, Andrzej Stawarski
Summary: Inflammatory bowel diseases (IBD) are chronic inflammatory diseases of the digestive tract with periods of remission and relapses. The etiopathogenesis is not fully understood, leading to only symptomatic treatment. There is a constant need to search for new high safety profile therapies for IBD.
JOURNAL OF CLINICAL MEDICINE
(2021)
Article
Gastroenterology & Hepatology
Kevin L. Winthrop, Severine Vermeire, Millie D. Long, Julian Panes, Siew C. Ng, Nicole Kulisek, Rajiv Mundayat, Nervin Lawendy, Ivana Vranic, Irene Modesto, Chinyu Su, Gil Y. Melmed
Summary: The incidence rates of herpes zoster in patients with ulcerative colitis remained stable during 7.8 years of tofacitinib exposure. Older age, lower weight, geographic region, and prior tumor necrosis factor inhibitor failure were identified as significant risk factors for herpes zoster.
INFLAMMATORY BOWEL DISEASES
(2023)
Letter
Gastroenterology & Hepatology
Dahham Alsoud, Bram Verstockt, Severine Vermeire
CLINICAL GASTROENTEROLOGY AND HEPATOLOGY
(2023)
Article
Medicine, Research & Experimental
Walter Reinisch, Adrian Serone, Xavier Hebuterne, Tanja Kuehbacher, Maria Klopocka, Xavier Roblin, Jens Brodbeck, Kim Etchevers, Rene Galien, Ethan Grant, Chantal Tasset, Oh Kyu Yoon, Shiva Zaboli, Severine Vermeire
Summary: This study examines the relationship between endoscopic, histologic, and molecular activity in patients with Crohn's disease. The findings suggest that histologic activity should be considered when assessing inflammatory burden in CD patients.
Article
Gastroenterology & Hepatology
Silvio Danese, Marc Ferrante, Brian G. Feagan, Laurent Peyrin-Biroulet, Toshifumi Hibi, William J. Sandborn, Stefan Schreiber, Timothy Ritter, Edward V. Loftus, Gerhard Rogler, Alessandra Oortwijn, Chohee Yun, Franck-Olivier Le Brun, Jason Dinoso, Jeremy Hsieh, Severine Vermeire
Summary: This study evaluated the efficacy and sustainability of filgotinib in treating moderately to severely active ulcerative colitis (UC) patients using the Mayo Clinic Score (pMCS) and patient-reported subscores. The results showed that treatment with filgotinib improved UC symptoms within 7 days and a higher proportion of patients achieved clinical remission at weeks 10 and 58.
AMERICAN JOURNAL OF GASTROENTEROLOGY
(2023)
Review
Gastroenterology & Hepatology
Pieter Sinonquel, Severine Vermeire, Frederik Maes, Raf Bisschops
Summary: This article reviews the latest developments in advanced GI endoscopy, focusing on screening, diagnosis, and surveillance of common upper and lower GI pathology. The importance of artificial intelligence in the field is emphasized, and the potential future impact of the literature is assessed.
GE PORTUGUESE JOURNAL OF GASTROENTEROLOGY
(2023)
Article
Gastroenterology & Hepatology
Wannee Kantasiripitak, Sebastian G. Wicha, Debby Thomas, Ilse Hoffman, Marc Ferrante, Severine Vermeire, Karen van Hoeve, Erwin Dreesen
Summary: The study aimed to develop a multi-model model-based software tool for guiding personalized infliximab induction treatment in pediatric inflammatory bowel disease patients. The study found that using the tool for individualized dosing improved the chances for children to achieve deep remission at 6 months.
JOURNAL OF CROHNS & COLITIS
(2023)
Article
Gastroenterology & Hepatology
Daan Jansen, Gwen Falony, Sara Vieira-Silva, Ceren Simsek, Tine Marcelis, Clara Caenepeel, Kathleen Machiels, Jeroen Raes, Severine Vermeire, Jelle Matthijnssens
Summary: This study found that the composition of gut viruses is associated with the pathophysiology and therapeutic success of inflammatory bowel disease (IBD), identifying two distinct gut viral configurations. These findings suggest a potential clinical relevance of gut viruses in the development and treatment of IBD.
JOURNAL OF CROHNS & COLITIS
(2023)
Review
Gastroenterology & Hepatology
Severine Vermeire, Virginia Solitano, Laurent Peyrin-Biroulet, Herbert Tilg, Silvio Danese, Hartmut Ehrlich, Didier Scherrer, Paul Gineste, Laurence d'Agay, Bruce E. Sands
Summary: Biologic agents and oral small molecules are the main treatments for IBD, but there is a need for new agents with novel mechanisms of action. miRNAs may be potential therapeutic targets for IBD. Obezafimod, a first-in-class oral small molecule, has shown promise in phase II trials for UC patients.
JOURNAL OF CROHNS & COLITIS
(2023)
Article
Gastroenterology & Hepatology
Julian Panes, Severine R. Vermeire, Geert D'Haens, Silvio Danese, Fernando Magro, Maciej Nazar, Manuela Le Bars, Marjolein Lahaye, Lioudmila Ni, Ivana R. Bravata, Daniel Gaya, Laurent Peyrin-Biroulet, Axel Dignass
Summary: This study compared two treatment strategies for Crohn's disease patients and found that regardless of whether the treatment was "treat-to-target" or "standard of care", ustekinumab was effective in improving the health-related quality of life and work productivity of patients over a 2-year follow-up period.
UNITED EUROPEAN GASTROENTEROLOGY JOURNAL
(2023)
Article
Immunology
Jeroen Geldof, Marie Truyens, Joao Sabino, Marc Ferrante, Jo Lambert, Hilde Lapeere, Tom Hillary, An Van Laethem, Kurt de Vlam, Patrick Verschueren, Elizaveta Padalko, Triana Lobaton, Severine Vermeire
Summary: The BELCOMID study confirms the benign course of COVID19 infection and vaccination in a large real-life population of patients with immune-mediated inflammatory diseases. However, the results emphasize the need for repeated vaccination and smoking cessation in IMID patients treated with immune-modulating therapies or systemic steroids during the pandemic.
FRONTIERS IN IMMUNOLOGY
(2023)
Article
Gastroenterology & Hepatology
S. Haenen, B. Verstockt, M. Ferrante, S. Vermeire, J. Sabino
Summary: Crohn's disease (CD) is a chronic inflammatory bowel disease that rarely affects the lungs. However, in this case report, CD presented with pulmonary manifestations as the first sign.
ACTA GASTRO-ENTEROLOGICA BELGICA
(2023)
Article
Gastroenterology & Hepatology
Johan Burisch, Mirabella Zhao, Selwyn Odes, Peter De Cruz, Severine Vermeire, Charles N. Bernstein, Gilaad G. Kaplan, Dana Duricova, Dan Greenberg, Hans O. Melberg, Mamoru Watanabe, Hyeong Sik Ahn, Laura Targownik, Valerie E. H. Pittet, Vito Annese, K. T. Park, Konstantinos H. Katsanos, Marte L. Hoivik, Zeljko Krznaric, Maria Chaparro, Edward V. Loftus, Peter L. Lakatos, Javier P. Gisbert, Willem Bemelman, Bjorn Moum, Richard B. Gearry, Michael D. Kappelman, Ailsa Hart, Marieke J. Pierik, Jane M. Andrews, Siew C. Ng, Renata D'Inca, Pia Munkholm
Summary: The cost of caring for patients with inflammatory bowel disease (IBD) continues to increase worldwide due to the steady increase in prevalence, the chronic nature of the diseases, expensive treatments, intensive monitoring, and their impact on productivity. This Commission urges evaluation of cost increases against improved disease management and the need for data interoperability and big data approaches to assess effectiveness and cost-effectiveness. International collaborations and novel care models should be sought to enhance education and training for clinicians, patients, and policy makers.
LANCET GASTROENTEROLOGY & HEPATOLOGY
(2023)
Article
Gastroenterology & Hepatology
Remo Panaccione, Eric B. Collins, Gil Y. Melmed, Severine Vermeire, Silvio Danese, Peter D. R. Higgins, Christina S. Kwon, Wen Zhou, Dapo Ilo, Dolly Sharma, Yuri Sanchez Gonzalez, Si-Tien Wang
Summary: Indirect evidence suggests that Upadacitinib may be more effective than other advanced therapies in achieving clinical response, clinical remission, and endoscopic response in patients with moderately to severely active ulcerative colitis over a one-year period, with similar safety profiles across different therapies.
CROHNS & COLITIS 360
(2023)
Article
Gastroenterology & Hepatology
Silvio Danese, Remo Panaccione, Maria T. Abreu, David T. Rubin, Subrata Ghosh, Axel Dignass, Anita Afzali, Douglas C. Wolf, Michael Chiorean, Severine Vermeire, Anjali Jain, Lorna Charles, Garrett Lawlor, Mark T. Osterman, Hsiuanlin Wu, James B. Canavan, Annkatrin Petersen, Jean-Frederic Colombel, Miguel Regueiro
Summary: This interim analysis examines the efficacy and safety of ozanimod treatment in patients with ulcerative colitis over a period of approximately 3 years. The results show that a high percentage of patients maintain clinical and mucosal efficacy during the treatment. No new safety concerns arise from long-term use of ozanimod.
JOURNAL OF CROHNS & COLITIS
(2023)
Article
Biochemical Research Methods
Bryan Linggi, Jonathan Cremer, Zhongya Wang, Tanja Van Viegen, Severine Vermeire, Pavine Lefevre, Lisa M. Shackelton, Vipul Jairath, Wendy Teft, Niels Vande Casteele, Bram Verstockt
Summary: Clinical trials of novel therapies for ulcerative colitis may benefit from immune cell profiling, but implementation is limited by the necessity of timely isolation and processing of peripheral blood mononuclear cells (PBMC). The use of Becton Dickinson Vacutainer CPTTM Cell Preparation Tubes (CPTTM) allows for delayed processing of PBMC, with ideal processing within 48 hours. Delayed processing may be considered for cell types that are robust to these conditions.
JOURNAL OF IMMUNOLOGICAL METHODS
(2023)